Return to search results.
Complete title: Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis
|Research Study Number||2067.00|
|Principal Investigator||George Georges, MD|
Research Study Description
Study Sites: Participants will receive treatment at the Seattle Cancer Care Alliance (SCCA) and the University of Washington.
Study Duration and Follow-up: Participation in the active treatment phase of the study (the transplantation) will last approximately 3 months. Following the transplantation, participants will receive regularly scheduled medical evaluations the first year. Thereafter, participants will have follow-up testing once a year through five years.
Eligibility Criteria (must meet the following to participate in this study)
Ages up to 70
Severe Systemic Sclerosis with evidence of moderate to severe skin involvement, lung involvement, history of kidney disease and failure of treatment with cyclophosphamide.
Availability of a matched sibling or unrelated stem cell donor
Other eligibility criteria may apply.
Exclusions (conditions that would prevent participation in this study)
Lack of suitable donor
Eligible for autologous transplant study (SCOT trial)
Severe organ dysfunction (such as heart, lung, liver, etc.)
Untreated psychiatric conditions
Lack of willingness to use contraceptive techniques
Other exclusion criteria may apply.
Autoimmune Diseases; Scleroderma; Systemic Sclerosis; Non-malignant Condition
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.